Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2012-08-23 Interim / Quarterly Rep…
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2012
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive interim financial report (Delårsrapport) for the period January to June 2012. It contains detailed financial statements, management commentary, operational highlights, and performance metrics. It is not a mere announcement (RPA) as it provides substantive financial data and analysis. Therefore, it is classified as an Interim/Quarterly Report. H2 2012
2012-08-23 Swedish
Interim / Quarterly Report 2012
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report, 1 January – 30 June 2012' and contains comprehensive financial statements, including consolidated profit performance summaries, balance sheet data, and detailed management commentary on business operations and R&D progress. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2012
2012-08-23 English
Klinisk fas Ia-studie med MIV-711 avslutad och fas Ib-studie inledd
Legal Proceedings Report Classification · 99% confidence The document is a press release dated August 21, 2012, announcing the completion of a Phase Ia clinical study for the drug candidate MIV-711 and the initiation of a Phase Ib study. It details clinical trial progress, safety evaluations, and future timelines for reporting results. This type of announcement, focusing on specific operational or clinical development milestones, is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were a slide deck, but given it's a press release about clinical trial updates, RNS serves as the most appropriate general regulatory/corporate update category when a more specific clinical trial update code is unavailable. Since it is a formal announcement of a corporate/scientific event, RNS is the best fit among the provided options, as it is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA).
2012-08-21 Swedish
Clinical phase Ia trial on MIV-711 complete and phase Ib trial commences
Regulatory Filings Classification · 85% confidence The document is a press release dated August 21, 2012, announcing the completion of a clinical phase Ia trial and the commencement of a phase Ib trial for the drug candidate MIV-711. It details the progress of clinical development, safety evaluations, and future expectations regarding trial results. This type of announcement, focusing on R&D progress and clinical trial updates, is best categorized as general corporate information related to investor relations or research activities, but it does not fit neatly into the specific categories like Earnings Release (ER), Interim Report (IR), or Audit Report (AR). Since it is a specific announcement about clinical development progress, it is most closely related to general corporate updates. Given the options, and noting that it is not a formal regulatory filing like a 10-K or a specific financial report, it falls under the general category of corporate news. However, none of the codes perfectly capture 'Clinical Trial Update'. Comparing the definitions, it is not a Management Report (MDA), nor a Financing Update (CAP). It is a specific operational update. In the absence of a dedicated 'R&D Update' code, and given that it is a formal announcement, it is best classified as a Regulatory Filing (RNS) as a general catch-all for significant, non-standard announcements, or potentially Investor Presentation (IP) if it were a presentation, but it is a press release. Given the nature of reporting on clinical trial progress, which is crucial for investors, and the lack of a better fit, RNS (Regulatory Filings - general regulatory announcements and fallback) is the most appropriate general classification for this type of specific corporate news release that isn't a financial report or management discussion.
2012-08-21 English
Major Shareholding Notification 2012
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding by 'Skandia Fonder AB' in 'Medivir Aktiebolag'. It explicitly shows the 'Before the transaction' and 'After the transaction' share quantities, voting rights, and resulting percentages. The key phrase is 'Reason for major shareholding notification Buy'. This structure perfectly matches the definition of a Major Shareholding Notification, which corresponds to the filing type code MRQ.
2012-07-04 English
Medivir meddelar att en interferonfri fas II-studie med TMC435 i kombination med daclatasvir kommer att inledas inom kort
Regulatory Filings Classification · 90% confidence The document is titled "Pressmeddelande" (Press Release) and announces the imminent start of a Phase II clinical study involving drug candidates TMC435 and daclatasvir for Hepatitis C treatment. It details the study design, patient population, and treatment arms. This type of announcement, detailing operational or clinical progress, is characteristic of an Earnings Release (ER) if it were quarterly results, but since it is a specific operational update (clinical trial initiation) that doesn't fit neatly into the core financial reports (10-K, IR, MRQ), it falls under a general corporate announcement. Given the options, it is a specific corporate update. While it could potentially be RNS (Regulatory Filings) as a fallback, the content is highly specific to clinical development, which often accompanies or substitutes for an Earnings Release (ER) in terms of providing operational highlights, or it could be considered a general announcement. However, since it is a press release announcing a specific operational event (clinical trial start) rather than a formal regulatory filing or a comprehensive financial report, and it is not a transcript, management discussion, or director dealing, the most fitting category for a significant, non-financial-result-focused operational update announced via press release is often RNS (Regulatory Filings) if no better fit exists, or ER if it's part of a regular reporting cycle. Given the focus is purely on clinical trial initiation and design, and it's a press release, RNS is the safest general regulatory/announcement category, though ER often covers operational highlights. Since it is not explicitly an earnings release but a clinical trial update, I will classify it as RNS (Regulatory Filings) as a broad announcement category, or potentially LTR if it were a legal matter, but it is not. Given the context of financial reporting databases, press releases announcing operational milestones often fall under RNS or ER. Since it is not a summary of financial results, RNS is the appropriate fallback for a specific corporate announcement.
2012-06-29 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.